ZBED5 Inhibitors
Chemical inhibitors of ZBED5 can modulate its activity through various biochemical pathways, each with its specific mechanism of action. Purvalanol A, for instance, selectively targets cyclin-dependent kinases (CDKs), pivotal in the cell cycle's control. By inhibiting these kinases, Purvalanol A disrupts processes that are crucial for the transcription factors regulated by ZBED5 to initiate transcription of genes. Similarly, PD98059 and U0126, both MEK inhibitors, and SP600125, a JNK inhibitor, function by dampening the MAPK/ERK and JNK pathways respectively. These pathways are known to influence DNA binding and transcription regulation, domains where ZBED5 operates. By impeding these kinases, the activity of ZBED5 in regulating gene expression is affected since the transcriptional responses it is implicated in are reduced.
Other inhibitors like LY294002 and Wortmannin exert their influence by targeting PI3K, a kinase involved in a vast array of cellular processes, including those governing transcription. The inhibition of PI3K would lead to a decrease in the transcriptional activity where ZBED5 is involved. SB203580, on the other hand, is a p38 MAPK inhibitor that can disrupt ZBED5's ability to regulate genes during stress or inflammatory conditions. IKK-16, which inhibits IKK in the NF-κB signaling pathway, can also attenuate the regulatory role of ZBED5 in gene transcription. Similarly, Rapamycin, by inhibiting mTOR, affects protein synthesis and cell growth, thus indirectly influencing the functional capacity of ZBED5. Lastly, compounds like Apigenin, Triptolide, and Chetomin, by inhibiting CK2, transcription factors, and HIF-1 respectively, can affect the phosphorylation status of proteins and the expression of genes where ZBED5's regulatory roles are critical, especially under conditions such as hypoxia. Through these diverse mechanisms, the activity of ZBED5 is modulated by these chemical inhibitors, each affecting a different aspect of its function in cellular processes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Purvalanol A | 212844-53-6 | sc-224244 sc-224244A | 1 mg 5 mg | $71.00 $291.00 | 4 | |
Purvalanol A is a selective inhibitor of cyclin-dependent kinases (CDKs). Inhibiting CDKs can disrupt the cell cycle, which may functionally inhibit ZBED5 by preventing the transcription factors that ZBED5 co-regulates from initiating the transcription of cell cycle-related genes. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of MEK, which is part of the MAPK/ERK pathway. ZBED5 has been implicated in DNA binding and transcription regulation, processes that are influenced by ERK signaling. Inhibition of MEK, therefore, could reduce the activity of ZBED5 by limiting the transcriptional responses that ZBED5 is involved in. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor. PI3K signaling is involved in numerous cellular processes including transcription. By inhibiting PI3K, LY294002 could reduce the activity of transcription factors and, consequently, the functional activity of ZBED5 in the nucleus. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. The p38 MAPK pathway is involved in stress responses and inflammation. By inhibiting p38 MAPK, SB203580 could impair the activity of ZBED5 by reducing its ability to regulate the transcription of genes under stress or inflammatory conditions. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $65.00 $267.00 | 257 | |
SP600125 is an inhibitor of JNK, which is part of the MAPK signaling pathways. JNK influences transcription factors and gene expression. By inhibiting JNK, SP600125 could reduce the regulatory impact of ZBED5 on gene expression related to stress responses where JNK is active. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2. By inhibiting MEK1/2, U0126 could indirectly inhibit ZBED5 by preventing the activation of downstream transcriptional regulators that ZBED5 might modulate. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent PI3K inhibitor. PI3K/Akt signaling can regulate numerous transcriptional events, potentially including those involving ZBED5. By inhibiting PI3K, wortmannin could reduce the nuclear functions of ZBED5 related to transcriptional regulation. | ||||||
IKK 16 | 1186195-62-9 | sc-204009 sc-204009A | 10 mg 50 mg | $219.00 $924.00 | 2 | |
IKK-16 is an inhibitor of IKK, which is part of the NF-κB signaling pathway. ZBED5, being associated with chromatin remodeling and gene transcription, may be influenced by NF-κB activity. By inhibiting IKK, IKK-16 could reduce the activity of ZBED5 in transcriptional regulation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor. mTOR is a key regulator of protein synthesis and cell growth. By inhibiting mTOR, rapamycin could indirectly inhibit ZBED5 by reducing the cellular resources and signaling pathways that ZBED5 needs to function. | ||||||
Apigenin | 520-36-5 | sc-3529 sc-3529A sc-3529B sc-3529C sc-3529D sc-3529E sc-3529F | 5 mg 100 mg 1 g 5 g 25 g 100 g 1 kg | $32.00 $210.00 $720.00 $1128.00 $2302.00 $3066.00 $5106.00 | 22 | |
Apigenin is a compound that can inhibit CK2, a protein kinase involved in a variety of cellular processes. By inhibiting CK2, apigenin could impact ZBED5's role in gene expression by altering the phosphorylation status of factors interacting with or regulating ZBED5. | ||||||